In recent years, transcatheter intervention techniques have emerged as a promising alternative for the closure of perimembranous ventricular septal defect (VSD). The advancements in trancatheter VSD ...
Occlutech, a leading innovator of implants to treat structural heart disease, today announced that it has obtained European CE Mark approval for its Perimembranous Ventricular Septal Defect (PmVSD) ...
MINNEAPOLIS, Sept. 10 AGA Medical Corporation ("AGA")announced today that it has received U.S. Food and Drug Administration (FDA)approval to market the AMPLATZER Muscular Ventricular Septal (VSD) ...
September 18, 2007 — The US Food and Drug Administration (FDA) has granted 510(k) clearance to 2 flexible digital endoscopes for diagnostic and therapeutic procedures and to a short-term catheter for ...
New transcatheter device for closing postinfarction ventricular septal defects may be safer than sur
Chicago, IL - A nonrandomized trial of a new ventricular septal occluder designed specifically for the closure of defects that occur post-MI suggests that while mortality is still high following the ...
(MENAFN- Market Press Release) June 10, 2025 3:02 am - Industry revenue for Transcatheter Vsd Occluder is estimated to rise to $1257.6 million by 2035 from $528.5 million of 2024. The revenue growth ...
A novel catheter technique for patching holes in the heart may make it possible for many patients to avoid surgery altogether and others to regain enough strength to safely undergo surgical repair at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback